Literature DB >> 21183738

Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.

Jinbo Liu1, Rui Chen, Gopal K Marathe, Maria Febbraio, Weilin Zou, Thomas M McIntyre.   

Abstract

RATIONALE: The phospholipid platelet-activating factor (PAF) stimulates all cells of the innate immune system and numerous cardiovascular cells. A single enzyme (plasma PAF acetylhydrolase [PAF-AH] or lipoprotein-associated phospholipase [Lp-PL]A(2)) in plasma hydrolyzes PAF, but significant controversy exists whether its action is pro- or antiinflammatory and accordingly whether its inhibition will slow cardiovascular disease.
OBJECTIVE: We sought to define how PAF and related short-chain oxidized phospholipids turnover in vivo and the role of PAF acetylhydrolase/Lp-PLA(2) in this process. METHODS AND
RESULTS: [(3)H-acetyl]PAF was hydrolyzed by murine or human plasma (t(1/2), 3 and 7 minutes, respectively), but injected [(3)H-acetyl]PAF disappeared from murine circulation more quickly (t(1/2), <30 seconds). [(3)H]PAF clearance was unchanged in PAF receptor(-/-) animals, or over the first 2 half-lives in PAF-AH(-/-) animals. [(3)H]PAF turnover was reduced by coinjecting excess unlabeled PAF or an oxidatively truncated phospholipid, and [(3)H]PAF clearance was slowed in hyperlipidemic apolipoprotein (apo)E(-/-) mice with excess circulating oxidatively truncated phospholipids. [(3)H]PAF, fluorescent NBD-PAF, or fluorescent oxidatively truncated phospholipid were primarily accumulated by liver and lung, and were transported into endothelium as intact phospholipids through a common mechanism involving TMEM30a.
CONCLUSIONS: Circulating PAF and oxidized phospholipids are continually and rapidly cleared, and hence continually and rapidly produced. Saturable PAF receptor-independent transport, rather than just intravascular hydrolysis, controls circulating inflammatory and proapoptotic oxidized phospholipid mediators. Intravascular PAF has access to intracellular compartments. Inflammatory and proapoptotic phospholipids may accumulate in the circulation as transport is overwhelmed by substrates in hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21183738      PMCID: PMC3057131          DOI: 10.1161/CIRCRESAHA.110.228742

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  56 in total

1.  Fluorescent, acyl chain-labeled phosphatidylcholine analogs reveal novel transport pathways across the plasma membrane of yeast.

Authors:  Shelley M Elvington; Fang Bu; J Wylie Nichols
Journal:  J Biol Chem       Date:  2005-10-04       Impact factor: 5.157

Review 2.  Platelet-activating factor and related lipid mediators.

Authors:  S M Prescott; G A Zimmerman; D M Stafforini; T M McIntyre
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

3.  cDNA cloning and expression of intracellular platelet-activating factor (PAF) acetylhydrolase II. Its homology with plasma PAF acetylhydrolase.

Authors:  K Hattori; H Adachi; A Matsuzawa; K Yamamoto; M Tsujimoto; J Aoki; M Hattori; H Arai; K Inoue
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

4.  Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine.

Authors:  Pamela K Hanson; Lynn Malone; Jennifer L Birchmore; J Wylie Nichols
Journal:  J Biol Chem       Date:  2003-07-03       Impact factor: 5.157

5.  A simple and precise method for the routine determination of platelet-activating factor in blood and urine.

Authors:  C A Demopoulos; N K Andrikopoulos; S Antonopoulou
Journal:  Lipids       Date:  1994-04       Impact factor: 1.880

Review 6.  Metabolism and atherogenic disease association of lysophosphatidylcholine.

Authors:  Gerd Schmitz; Katharina Ruebsaamen
Journal:  Atherosclerosis       Date:  2009-06-06       Impact factor: 5.162

7.  Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein.

Authors:  Alison A Gardner; Ethan C Reichert; Matthew K Topham; Diana M Stafforini
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

8.  The platelet-activating factor acetylhydrolase from human erythrocytes. Purification and properties.

Authors:  D M Stafforini; E N Rollins; S M Prescott; T M McIntyre
Journal:  J Biol Chem       Date:  1993-02-25       Impact factor: 5.157

Review 9.  Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).

Authors:  Diana M Stafforini
Journal:  Cardiovasc Drugs Ther       Date:  2008-10-24       Impact factor: 3.727

10.  Platelet activating factor receptor (PAF-R) is found in a large endosomal compartment in human umbilical vein endothelial cells.

Authors:  K Ihida; D Predescu; R P Czekay; G E Palade
Journal:  J Cell Sci       Date:  1999-02       Impact factor: 5.285

View more
  16 in total

Review 1.  Atherosclerosis: current pathogenesis and therapeutic options.

Authors:  Christian Weber; Heidi Noels
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  An essential role for platelet-activating factor in activating mast cell migration following ultraviolet irradiation.

Authors:  Rommel Chacón-Salinas; Limo Chen; Alma D Chávez-Blanco; Alberto Y Limón-Flores; Ying Ma; Stephen E Ullrich
Journal:  J Leukoc Biol       Date:  2013-09-05       Impact factor: 4.962

3.  Preferential hydrolysis of truncated oxidized glycerophospholipids by lysosomal phospholipase A2.

Authors:  Akira Abe; Miki Hiraoka; Hiroshi Ohguro; John J Tesmer; James A Shayman
Journal:  J Lipid Res       Date:  2016-12-19       Impact factor: 5.922

Review 4.  Bioactive oxidatively truncated phospholipids in inflammation and apoptosis: formation, targets, and inactivation.

Authors:  Thomas M McIntyre
Journal:  Biochim Biophys Acta       Date:  2012-03-16

Review 5.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

6.  Biosynthesis of oxidized lipid mediators via lipoprotein-associated phospholipase A2 hydrolysis of extracellular cardiolipin induces endothelial toxicity.

Authors:  Justin R Buland; Karla J Wasserloos; Vladimir A Tyurin; Yulia Y Tyurina; Andrew A Amoscato; Rama K Mallampalli; Bill B Chen; Jing Zhao; Yutong Zhao; Solomon Ofori-Acquah; Valerian E Kagan; Bruce R Pitt
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-05-27       Impact factor: 5.464

Review 7.  Role of phospholipid oxidation products in atherosclerosis.

Authors:  Sangderk Lee; Konstantin G Birukov; Casey E Romanoski; James R Springstead; Aldons J Lusis; Judith A Berliner
Journal:  Circ Res       Date:  2012-08-31       Impact factor: 17.367

8.  The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.

Authors:  Miao-miao Hu; Jie Zhang; Wen-yi Wang; Wen-yu Wu; Yan-ling Ma; Wei-hai Chen; Yi-ping Wang
Journal:  Acta Pharmacol Sin       Date:  2011-08-15       Impact factor: 6.150

9.  Unraveling the PAF-AH/Lp-PLA2 controversy.

Authors:  Diana M Stafforini; Guy A Zimmerman
Journal:  J Lipid Res       Date:  2014-07-09       Impact factor: 5.922

Review 10.  Lipid peroxidation generates biologically active phospholipids including oxidatively N-modified phospholipids.

Authors:  Sean S Davies; Lilu Guo
Journal:  Chem Phys Lipids       Date:  2014-04-02       Impact factor: 3.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.